Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays

Haemophilia

Volumn 21, Issue 6, 2015, Pages 832-836

  Sorensen M H ^a   Andersen, S ^a   Ezban, M ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Chromogenic assay; ELISA; Factor IX; Haemophilia B; Nonacog beta pegol; One stage clotting assay

Indexed keywords

BLOOD CLOTTING FACTOR 9; N 9 GP; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; CALCIUM; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; BLOOD CLOTTING TEST; BLOOD EXAMINATION; CHROMOGENIC ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG ACTIVITY; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; ONE STAGE CLOTTING ASSAY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; BLOOD CLOTTING; COMPARATIVE STUDY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PLASMA; PROCEDURES;

BLOOD COAGULATION; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR IX; HUMANS; PLASMA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84946497249     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12680     Document Type: Article

References (20)

1. Ostergaard H, Bjelke JR, Hansen L et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
2. Collins PW, Moss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305-12.
3. Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 2013; 13: 1287-97.
4. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87(Suppl. 1): S33-9.
5. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
6. Ivens IA, Baumann A, McDonald TA, Humphries TJ, Michaels LA, Mathew P. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013; 19: 11-20.
7. Collins PW, Young G, Knobe K et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124: 3880-6.
8. Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia 2014; 20(Suppl. 4): 23-8.
9. Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia 2014; 20(Suppl. 4): 36-42.
10. Bowyer A, Hillarp A, Persson M, Ezban M, Persson P, Kitchen S. The laboratory measurement of a glycopegylated recombinant FIX, N9-GP: a two centre study (abstract EHF11). J Thromb Haemost 2014; 12: 32-3.
11. Bowyer A, Hillarp A, Persson M, Ezban M, Persson P, Kitchen S. The laboratory measurement of a glycopegylated recombinant FVIII, N8-GP: a two centre study (abstract EHF06). J Thromb Haemost 2014; 20: 31.
12. Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica 2013; 98: 1980-7.
13. Holm PK, Sørensen MH, Hermit BM, Ezban M. The activity of GlycoPEGylated recombinant FIX (N9-GP) can be measured in two-stage chromogenic and one-stage clotting assays (abstract PB 3.49-1). J Thromb Haemost 2014; 11(S2): 828.
14. Lochu A, Romari N, Beltran J, Magdelaine A, Ezban M, Hermit MB. Influence of FIX and FVIII PEGYLATION on FIX and FVIII activity based on APTT assays (abstract PB 4.54-1). J Thromb Haemost 2014; 11(S2): 970.
15. Sommer JM, Moore N, McGuffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294-300.
16. Sommer JM, Buyue Y, Bardan S et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost 2014; 112: 932-40.
17. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
18. Moser KA, Adcock Funk DM. Chromogenic factor VIII activity assay. Am J Hematol 2014; 89: 781-4.
19. Holm PK, Sørensen MH, Hermit MB, Ezban M. The biological activity of GlycoPEGylated recombinant FIX (N9-GP) is similar in two-stage chromogenic assays, in Synthafax-based one-stage clot assay and in TEG assay using blood from hemophilia B patients (poster abstract 8). Haemophilia 2014; 20: 24.
20. Hermit MB, Sorensen MH, Ezban M, Lochu A, Magdelaine A. Pegylation of fix influences the clotting time in aptt assays. use of product specific standard eliminates peg interference. Haemophilia 2013; 19: 36.